Psychedelic-Assisted Therapy: From Research to Policy Implementation
Abstract
This lecture will delve into the evolution and implementation of psychedelic-assisted therapy (PAT) in Switzerland, exploring its progression from early research leadership in the 1990s to contemporary clinical practice. Since 2014, exceptional permits for the therapeutic use of substances like LSD, MDMA, and psilocybin have facilitated thousands of treatments under a regulated framework. The presentation will highlight milestones such as the establishment of therapist training programs by the Swiss Medical Association for Psychedelic Therapy (SÄPT), as well as the integration of PAT into mental health care. Key challenges, including scaling high-quality training, maintaining rigorous documentation, and fostering professional networks, will also be discussed. Drawing on the meddical history of Switzerland, the lecture will offer insights into the global potential for PAT to transform mental health care while upholding ethical and clinical standards.
Speaker
|
Dr. Helena Aicher is a postdoctoral researcher engaged in studies investigating ayahuasca-inspired formulations and the processes involved in psychedelic-assisted therapy. She also works as a therapist, facilitating the limited medical use of psychedelics such as LSD, psilocybin, and MDMA, primarily in group settings. As a key member of the Swiss Medical Association for Psychedelic Therapy (SÄPT), she plays an active role in therapist training, focusing on developing robust programs that integrate theory, practice, and ethics. Dr. Aicher operates at the intersections of science and practice, contributing to the advancement of psychedelic therapy through innovative research, clinical work, and education.
|